Crinetics Pharmaceuticals Investor Conference Participation
![Crinetics Pharmaceuticals Investor Conference Participation](https://investorshangout.com/images/blog/ihnews-Crinetics%20Pharmaceuticals%20Investor%20Conference%20Participation.jpg)
Crinetics Pharmaceuticals Investor Conference Participation
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company dedicated to the discovery and commercialization of groundbreaking therapeutics for endocrine diseases and related tumors, has announced its participation in two significant investor conferences. Company management will engage in fireside chats at both the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference, taking place in September.
Morgan Stanley 22nd Annual Global Healthcare Conference
During the Morgan Stanley 22nd Annual Global Healthcare Conference, Crinetics Pharmaceuticals will host a fireside chat on Wednesday, September 4, at 5:35 p.m. Eastern Time. This session will provide insights into the company’s innovative approaches and latest advancements.
Webcast Details
The live webcast can be accessed HERE.
Cantor Global Healthcare Conference
Crinetics will also participate in the Cantor Global Healthcare Conference. The fireside chat is scheduled for Wednesday, September 18, at 8:35 a.m. Eastern Time, where Crinetics will discuss their strategic vision and upcoming milestones.
Webcast Details
The live webcast link for this event is available HERE.
Accessing Webcasts
Both live and archived webcasts from these conferences will be made available on the Events & Presentations page within the Investors section of Crinetics’ official website at www.crinetics.com/events.
Meeting Opportunities
Investors interested in arranging one-on-one meetings with management during the conferences are encouraged to reach out through their respective conference representatives, facilitating deeper discussions about Crinetics’ ongoing projects and future developments.
About Crinetics Pharmaceuticals
As a clinical-stage pharmaceutical company, Crinetics Pharmaceuticals is focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and tumors. Among the company’s notable candidates is paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, now in Phase 3 clinical trials for acromegaly and Phase 2 trials for carcinoid syndrome related to neuroendocrine tumors.
Additional Developments
Furthermore, Crinetics is advancing atumelnant (CRN04894), another first-in-class, oral ACTH antagonist, which is nearing completion of Phase 2 clinical studies for conditions such as congenital adrenal hyperplasia and Cushing’s disease. The company emphasizes that all drug candidates are small-molecule entities developed through extensive in-house research efforts.
Addressing Diverse Conditions
Crinetics also aims to address various endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, diabetes, obesity, and cancer indications targeting GPCRs. Their commitment to innovative therapies highlights their importance in the medical community.
Investor Contacts
If you have inquiries regarding investments or wish to contact management, please reach out to:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media Contacts
For media inquiries, please contact:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
Frequently Asked Questions
What is the focus of Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals specializes in developing therapeutics for endocrine diseases and related tumors.
What are the upcoming investor conferences Crinetics is participating in?
Crinetics will be participating in the Morgan Stanley and Cantor Global Healthcare Conferences.
Who can arrange meetings with Crinetics management?
Investors can arrange meetings through their conference representatives.
What is paltusotine?
Paltusotine is an oral somatostatin receptor type 2 agonist in Phase 3 clinical development for acromegaly.
How can I access the webcasts from the conferences?
The webcasts will be available on the Events & Presentations page of the Crinetics website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- ARCpoint Conference Call for Q2 2024 Financial Results
- Ultragenyx Announces Participation in Key Investor Conferences
- GoHealth at H.C. Wainwright Annual Investment Conference
- Fuel Tech's Upcoming Presentation at Investment Conference
- Dave Inc. to Attend Key Investor Conferences in September
- DMG Blockchain Solutions to Showcase at 2024 Gateway Conference
- Pulmonx to Showcase Innovations at Key Growth Conference
- SPS Commerce to Showcase Innovations at Citi's Conference
- Pactiv Evergreen Inc. to Attend Jefferies Industrials Conference
- Definitive Healthcare to Showcase Insights at Key Conference
- CarGurus Participation at Citi's 2024 TMT Conference
- Sana Biotechnology to Showcase at Upcoming Investor Conferences
- Nvidia's Earnings Report Signals Caution for Investors
- CEO Scott Solomon to Address Cash Logistics at PBC Conference
- CTBUH Conference: Addressing Urban Density Challenges
- NANO Nuclear Energy to Showcase at Global Investment Conference
- AnaptysBio to Attend Key Investor Conferences in September
- Vericel Corporation's Upcoming Presentation at Healthcare Conference
- MediaAlpha to Speak at Goldman Sachs Conference
- U.S. Global Investors Expands JETS ETF to Colombia
- Discover Economics Insights at the Virtual Banking Conference
- Opendoor to Showcase at Goldman Sachs Conference
- Inozyme Pharma Set to Participate in Healthcare Conference
- Gaia Reveals September Investor Conference Schedule
- La Rosa Holdings Corp. to Present at Investment Conference
Recent Articles
- BEN Partners with INTERVENT and Members Only Health for AI in Healthcare
- Credicorp Ltd. Declares Special Cash Dividend Announcement
- Nokia Addresses Stock Trading Activity Concerns
- Global Process Analytical Technology Market Insights
- Wealth Competition: Bettencourt Meyers vs. Walton
- Virginia Credit Union Welcomes New Board Members Post Merger
- EDP Renewables Promotes Gabriel Yamal to EVP Role
- Pending Home Sales Decline in July Highlights Market Trends
- Exor N.V. Announces Update to 2024 Corporate Calendar
- Growth of Container Security Market to USD 13.10 Billion
- Bollinger Motors Expands EV Dealer Network with TEC Equipment
- BlackRock Adjusts Shareholding in Novonesis
- Rising Demand for Conductive Foam in Electronics
- Avricore Health Reports Strong Mid-Year Growth and Profitability
- The Parabolic Rise of ASML Holding and Palantir Technologies
- Cylindrical LiFePO4 Battery Market Growth Insights
- Fingerprint Cards AB Launches Innovative FPC AllKey System
- WISeKey's WISe.ART Unveils NFTs from The Three Gates of Wisdom
- Salesforce Surpasses Expectations with Impressive Earnings
- Aircraft Rescue and Firefighting Vehicles Market Growth
- Nvidia Earnings Report Analysts Await Major Insights
- HP Inc. Focuses on Cost Cuts and AI PCs for Growth
- SL Green Realty Corp. Announces BofA Global Conference Panel
- Peloton Interactive to Speak at Goldman Sachs Conference
- InspireSemi to Issue Shares for Interest Payment on Debentures